Docs rate top specialty reps

Share this article:
Docs rate top specialty reps
Docs rate top specialty reps

Physicians were asked to rank the companies that have the best general sales reps, specialty sales reps and medical science liaisons as part of “Specialty Reps 2007: An Influential Force,” a recent Verispan survey of 4,000 physicians from across 24 specialties.

Here's a look at what docs from each specialty had to say about the specialty sales reps that serve them.

Cardiologists rated Pfizer, Merck and Novartis first, second and third respectively as the companies with the best specialty sales forces.
Gastroenterologists rated AstraZeneca, TAP and Abbott as the top three sales forces for specialty reps.

Neurologists/neurosurgeons ranked Pfizer, GlaxoSmithKline, UCB and Novartis as having the best specialty reps.
 
OB/GYNs ranked Wyeth, Ortho-McNeil and Bayer first, second and third, respectively in terms of best specialty reps.
Oncologists rated Genentech, Amgen and Novartis as having the best specialty reps.

Ophthalmologists ranked Alcon, Allergan and Pfizer as the leasing sales forces in terms of specialty reps.

Pediatricians ranked Merck, GlaxoSmithKline and Shire as the top three sales forces for specialty reps.

Psychiatrists ranked Eli Lilly, Janssen and Pfizer as having the leading specialty sales reps.

Urologists rated Pfizer, Sanofi-Aventis and GlaxoSmithKline first, second and third, in terms of best specialty reps.

Share this article:

Email Newsletters

More in News

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union

Rep access continues to shrink

Rep access continues to shrink

Sales reps are experiencing even more limited physician access, according to a report by Chicago consultancy ZS Associates.

Allergan touts reorg, plans to lay off 13% of workforce

Allergan touts reorg, plans to lay off 13% ...

Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.